Natco Pharma (Nannapaneni V Chowdary, Chairman and Managing Director) has launched its first nanotechnology drug Albupax. Albupax is the first generic version of the international brand - Abraxane of Abraxis Bio-sciences, USA.
Albupax, which is the brand name of Natco consists of Paclitaxel in an Albumin bound nano-particle form.
Albupax is used in the treatment of breast cancer. It has been indigenously developed by Natco in India and is the first albumin bound Paclitaxel in nano- particle to be developed in India.
Each 100 mg vial of Albupax has been priced at Rs 11,500. The estimated Indian market for this product is in the region of Rs 1,500 million and NATCO expects Albupax to garner a reasonable share of this market.